From bulk, single-cell to spatial RNA sequencing
X Li, CY Wang - International journal of oral science, 2021 - nature.com
RNA sequencing (RNAseq) can reveal gene fusions, splicing variants, mutations/indels in
addition to differential gene expression, thus providing a more complete genetic picture than …
addition to differential gene expression, thus providing a more complete genetic picture than …
Cell death-based treatment of lung adenocarcinoma
TV Denisenko, IN Budkevich, B Zhivotovsky - Cell death & disease, 2018 - nature.com
The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …
The emerging clinical relevance of genomics in cancer medicine
The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …
approaches has revolutionized our understanding of the genomic underpinnings of cancer …
Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA–C can
result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or …
result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or …
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and …
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors …
evaluated in two phase I studies in patients with advanced or metastatic solid tumors …
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
Background Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of
various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with …
various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with …
Non-small-cell lung cancers: a heterogeneous set of diseases
Z Chen, CM Fillmore, PS Hammerman, CF Kim… - Nature Reviews …, 2014 - nature.com
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …
diverse pathological features. During the past decade, in-depth analyses of lung cancer …
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
The emerging complexity of gene fusions in cancer
F Mertens, B Johansson, T Fioretos… - Nature Reviews Cancer, 2015 - nature.com
Structural chromosome rearrangements may result in the exchange of coding or regulatory
DNA sequences between genes. Many such gene fusions are strong driver mutations in …
DNA sequences between genes. Many such gene fusions are strong driver mutations in …
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
M Riaud, J Maxwell, I Soria-Bretones… - Nature Reviews …, 2024 - nature.com
The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …